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Two centuries ago in 1817, James Parkinson provided the first medical description of Parkinson’s disease, later
refined by Jean-Martin Charcot in the mid-to-late 19th century to include the atypical parkinsonian variants (also
termed, Parkinson-plus syndromes). Today, Parkinson’s disease represents the second most common
neurodegenerative disorder with an estimated global prevalence of over 10 million. Conversely, atypical
parkinsonian syndromes encompass a group of relatively heterogeneous disorders that may share some clinical
features with Parkinson’s disease, but are uncommon distinct clinicopathological diseases. Decades of scientific
advancements have vastly improved our understanding of these disorders, including improvements in in vivo
imaging for biomarker identification. Multimodal imaging for the visualization of structural and functional brain
changes is especially important, as it allows a ‘window’ into the underlying pathophysiological abnormalities. In this
article, we first present an overview of the cardinal clinical and neuropathological features of, 1) synucleinopathies:
Parkinson’s disease and other Lewy body spectrum disorders, as well as multiple system atrophy, and 2)
tauopathies: progressive supranuclear palsy, and corticobasal degeneration. A comprehensive presentation of well-
established and emerging imaging biomarkers for each disorder are then discussed. Biomarkers for the following
imaging modalities are reviewed: 1) structural magnetic resonance imaging (MRI) using T1, T2, and susceptibility-
weighted sequences for volumetric and voxel-based morphometric analyses, as well as MRI derived visual
signatures, 2) diffusion tensor MRI for the assessment of white matter tract injury and microstructural integrity, 3)
proton magnetic resonance spectroscopy for quantifying proton-containing brain metabolites, 4) single photon
emission computed tomography for the evaluation of nigrostriatal integrity (as assessed by presynaptic dopamine
transporters and postsynaptic dopamine D2 receptors), and cerebral perfusion, 5) positron emission tomography for
gauging nigrostriatal functions, glucose metabolism, amyloid and tau molecular imaging, as well as
neuroinflammation, 6) myocardial scintigraphy for dysautonomia, and 7) transcranial sonography for measuring
substantia nigra and lentiform nucleus echogenicity. Imaging biomarkers, using the ‘multimodal approach’, may aid
in making early, accurate and objective diagnostic decisions, highlight neuroanatomical and pathophysiological
mechanisms, as well as assist in evaluating disease progression and therapeutic responses to drugs in clinical trials.
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With an estimated global prevalence of more than 10
million cases [1], Parkinson’s disease (PD) represents the
second most common neurodegenerative disorder after
Alzheimer’s disease (AD), associated with momentous
socioeconomic burden and immeasurable human suffer-
ing. The first medical description of PD was provided by
James Parkinson nearly two centuries ago. Since then, the
precise conceptualization of this disease has evolved con-
siderably [2]. In the mid-to-late 19th century, Jean-Martin
Charcot curiously illustrated the atypical parkinsonian var-
iants and likened the unusually extended extremities of
one of his patients to ‘rigid bars’ [2]. Decades of scientific
advances in diagnostics, neuroimaging and clinicopatho-
logical correlations have permitted a better understanding
of PD and related atypical parkinsonian syndromes (PS)
(also termed Parkinson-plus syndromes).
PD is characterized by the death of dopaminergic neu-
rons within the substantia nigra pars compacta (SNpc)
due to intraneuronal aggregation of α-synuclein in the
form of Lewy bodies and Lewy neurites in the majority
of cases [3]. The resultant dopaminergic denervation in
the basal ganglia combined with dysfunction in non-
dopaminergic systems due to more widespread neurode-
generation leads to classical motor and non-motor
symptoms. Motor manifestations of PD include bradyki-
nesia, rigidity, resting tremor, and postural and gait
disturbances; whereas, non-motor features may include
depression, olfactory and autonomic dysfunction, sleep
disorders, psychiatric symptoms, pain, fatigue and cogni-
tive impairment [3]. Conversely, atypical PS encompass
a group of relatively heterogeneous disorders that may
share some clinical features with PD, but are distinct
clinicopathological entities.
Neurodegenerative diseases are now classified on the
basis of the predominant protein aggregates that
characterize the neuropathology. These proteins are be-
lieved to play a critical role in disease pathogenesis. In the
case of parkinsonian disorders, the predominant under-
lying neuropathologies include: 1) α-synucleinopathies,
such as the full clinical spectrum of PD with and without
cognitive impairment/dementia, dementia with Lewy bod-
ies (DLB), and multiple system atrophy (MSA); and 2)
tauopathies, including progressive supranuclear palsy
(PSP) and corticobasal degeneration (CBD). A small
proportion of cases, e.g. presenting with a corticobasal
syndrome, are classified as TDP-43opathies (pathology of
transactive response DNA binding protein of 43 kDa).
Overlap in symptomatology, clinical heterogeneity in
disease presentation and progression, and variability in
response to dopaminergic medications can make the dif-
ferential diagnosis of parkinsonian disorders challenging
at times, especially at early disease stages. Accurate and
prompt diagnosis is vital to accommodate differentialprognostic and disease management approaches, and to
assess the efficacy of experimental therapeutic interven-
tions in clinical trials. Imaging plays a pivotal role in this
regard by providing an in vivo opportunity to visualize the
neuroanatomical and functional signatures of these disor-
ders, as well as identifying disease-specific biomarkers of
the underlying neurodegenerative processes. These bio-
markers have the potential to eventually serve as reliable
neuropathologic indicators to improve the sensitivity and
specificity of clinical diagnoses.
This review will present a brief overview of the promin-
ent clinical and neuropathological features of parkinsonian
disorders, followed by a comprehensive presentation of
well-established and promising imaging biomarkers with
emphasis on their distinguishing characteristics in PD and
atypical PS.
Methods
The literature was comprehensively reviewed via the
PubMed database using the following disease-specific key-
words: ‘Parkinson*’, ‘Lewy*’, ‘multiple system atrophy’, ‘corti-
cobasal degeneration’, ‘progressive supranuclear palsy’; −
combined with one of the modality-specific terms: ‘mag-
netic resonance imaging’, ‘positron emission tomography’,
‘single-photon emission computed tomography’, ‘diffusion
tensor’, ‘proton spectroscopy’, ‘myocardial scintigraphy’, and
‘transcranial sonography’. Acronyms, e.g. ‘MRI’ for ‘mag-
netic resonance imaging’, were entered as appropriate.
Articles were restricted to those: 1) in English, and 2) pub-
lished between January 1, 1995 and February 29, 2016. All
identified abstracts were screened for relevance and the
most pertinent articles were reviewed in full, with further
examination of the corresponding reference lists, which
became the foundation for this review.
Clinical and neuropathological features
α-synucleinopathies – Lewy body spectrum disorders and
multiple system atrophy
Lewy body spectrum disorders (LBD) include a clinical
spectrum of closely-related α-synucleinopathies that share
clinical characteristics of levodopa-responsive parkinson-
ism, cognitive impairment, fluctuations in attention and
alertness, and visual hallucinations to varying degrees.
These disorders include PD with or without mild cognitive
impairment (MCI), Parkinson’s disease dementia (PDD)
and dementia with Lewy bodies (DLB). While motor
symptoms predominate at early PD stages, cognitive
dysfunction generally emerges later. Until recently, the on-
set of parkinsonism relative to dementia manifestation
was used as an arbitrary criterion to clinically distinguish
PDD and DLB using a ‘one-year rule’: dementia onset
within 12-months of or contemporarily with motor
dysfunction qualified as DLB, whereas parkinsonism had
to precede dementia by at least one-year in PDD [4].
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the International Parkinson and Movement Disorder
Society propose eliminating this arbitrary one-year rule.
All patients fulfilling diagnostic criteria for PD are diag-
nosed as such, independent of when dementia develops.
Predominant brainstem Lewy pathology is seen in PD,
whereas more diffuse Lewy pathology involving the brain-
stem, limbic and neocortical regions is typical of DLB and
PDD. Concurrent AD pathology (amyloid-beta [Aβ]
plaques and neurofibrillary tangles) frequently co-exists in
DLB and may even be seen in PDD, thus contributing to
substantial clinical heterogeneity in these disorders [4, 5].
Multiple system atrophy (MSA) represents an adult-
onset, heterogeneous neurodegenerative disease with pro-
gressive autonomic and/or cerebellar dysfunction, and en-
compasses three disorders that were formerly considered
distinct clinicopathological conditions: Shy-Drager
syndrome, olivopontocerebellar atrophy, and striatonigral
degeneration [6]. Common clinical symptoms of MSA
include motor features, such as parkinsonism, cerebellar
ataxia and postural abnormalities; and non-motor features
secondary to autonomic failure involving multiple physio-
logical systems – cardiovascular and urogenital being the
most frequently affected [6]. Broadly, MSA is subgrouped
into the parkinsonian subtype (MSA-P) if parkinsonism is
the predominant presentation; or cerebellar subtype
(MSA-C) with characteristic cerebellar symptomatology.
Histopathological examination reveals oligodendroglial
cytoplasmic inclusions (Papp-Lantos bodies) housing
misfolded α-synuclein protein with varying degrees of
degeneration in olivopontocerebellar and striatonigral
regions [6].
Tauopathies – progressive supranuclear palsy and
corticobasal degeneration
Formally described in 1964 by Steele, Richardson and
Olszewski, PSP is a progressive neurodegenerative dis-
ease associated with axial rigidity, bradykinesia, postural
instability, vertical supranuclear gaze palsy, speech and
swallowing dysfunction, as well as fronto-executive cog-
nitive and behavioural manifestations [7, 8]. Gait impair-
ment typically progresses at an accelerated rate in PSP
relative to PD, with early falls as a prominent feature.
Several variants have been identified that challenge the
classical clinicopathological characterization of the PSP
syndrome. For example, unlike the classical syndrome
(now referred to as Richardson syndrome or PSP-R), the
PSP-parkinsonism variant (PSP-P) exhibits more con-
spicuous limb rigidity with bradykinesia and/or tremor
with moderate levodopa response in a proportion of
patients, without early ocular or postural disturbances [8].
Vertical gaze palsy is an important diagnostic feature of
PSP, although it may not be evident at early disease stages
[8]. Histopathologically, evidence of neurofibrillary tanglescomposed of misfolded 4-repeat tau protein, neuropil
threads and star-shaped tufted astrocytes are seen, mainly
in the basal ganglia, brainstem and diencephalon [7, 8].
The classical syndrome associated with CBD pathology
involves the combination of basal ganglionic and cortical
features. Strikingly asymmetric limb rigidity, dystonia,
and bradykinesia are basal ganglionic features, whereas
typical cortical features include limb apraxia, aphasia,
alien limb phenomenon, stimulus-sensitive myoclonus
as well as other cognitive and behavioural impairments
[9]. Neuropathological findings reveal abnormal accu-
mulation of hyperphosphorylated 4-repeat tau in the
form of swollen, achromatic (i.e., ballooned) neurons,
and in glial cells as astrocytic plaques [9]. Diagnostic
accuracy of CBD is modest due to extensive neuropatho-
logical heterogeneity and merely 25–56% of cases are
correctly diagnosed antemortem [9, 10]. This represents
a foremost obstacle in research studies, where antemor-
tem diagnosis is confounded by a host of other under-
lying pathologies with overlapping features, including
AD, PSP and other tau-positive and tau-negative (largely
TDP-43 positive) forms of frontotemporal lobar degen-
eration (FTD) [11]. A broader term, corticobasal
syndrome (CBS), has thus been suggested to describe
clinical characterization of this disorder without histo-
pathological confirmation.
Magnetic resonance imaging in Parkinsonian
disorders
Structural magnetic resonance imaging
Magnetic resonance imaging (MRI) takes advantage of
abundant hydrogen atoms and strong magnetic fields to
image brain tissues non-invasively. Conventional structural
MRI uses distinct pulse sequences to obtain T1-weighted
(T1), T2-weighted (T2), proton-density weighted,
fluid-attenuated inversion recovery (FLAIR) and/or
susceptibility-weighted (SW) scans. SW imaging is
sensitive to magnetic inhomogeneity effects, particu-
larly due to iron accumulation, hemorrhages, and/or
slow venous blood flow, allowing for an enhanced tis-
sue contrast. These images can be analyzed selectively
or in combination to obtain volumes of brain struc-
tures, regional cortical thickness, and to identify re-
gional tissue abnormalities. Such structural profiles,
including patterns and rates of atrophy, are important
areas of research from a biomarker viewpoint.
Structural MRI profiles of Parkinson’s disease
Structural brain changes tend to be subtle in early PD
and may not be apparent on conventional MRI. Voxel-
based morphometry (VBM) studies have identified
reduced gray matter (GM) volumes compared to controls
in the frontal lobe [12], right hippocampus, and left anter-
ior cingulate and superior temporal gyri [13]. Pitcher et al.
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putaminal volumes respectively in PD patients relative to
controls [14]. Tinaz and colleagues applied MRI coupled
with an automated surface reconstruction method and re-
ported cortical thinning in the orbitofrontal, ventrolateral
prefrontal, and occipitoparietal cortical regions in PD
subjects, along with striatal volumetric reductions subcor-
tically [15]. However, normal striatal volumes have also
been reported in PD, whereas brainstem volumes were
found to be significantly reduced in MSA and PSP [16]. In
a recent VBM study, Chen et al. found significant volu-
metric loss in the olfactory bulb and tracts of PD patients,
versus MSA and controls, and the global olfactory bulb
volume inversely correlated with PD duration [17].
As PD is associated with substantia nigra (SN) path-
ology, several investigations have aimed to identify SN
volumetric differences on MRI, although with varying
results. Some studies noted no volumetric differences in
SN compared to controls [18, 19], while others identified
a decrease [20] and even an increase in SN volume [21].
Minati et al. reported smaller SN with a characteristic
lateral-to-medial loss [20], whereas Péran and colleagues
found no volumetric changes, but identified an increased
R2* transverse relaxation rate in SN [19]. More recent
research using ultra-high-field MRI allowed for finer
structural resolution of SN and helped to clarify volu-
metric discrepancies. At 7 Tesla (T), Cho et al. described
‘smudging’ or loss of the fine boundaries between SN
and crus cerebri, which appeared relatively ‘serrated’ in
PD patients [22]. Similarly, the identification of a three-
layered anatomical organization of SN became evident
on SW 7 T-MRI in normal controls, which was less ap-
parent or unidentifiable in PD subjects. This SW-derived
architectural change of SN at 7T allowed excellent
discrimination of PD versus normal controls (sensitivity
100%, specificity 96.2%) [23]. Such morphological alter-
ations, presumably due to degeneration and iron accu-
mulation in SNpc, may produce expanded hypointense
regions on MRI and explain the increased SN volumes
reported in some studies at lower resolutions. These
changes also align with longitudinal reports of increased
R2* relaxation rates of SN in PD (~10.2% in pars com-
pacta; 8.1% in pars reticula over a three-year period)
[24], which can result from ferritin-induced field inho-
mogeneities and are shown to correlate with worsening
motor symptoms. In a recent 36-month longitudinal
study, a greater change in R2* relaxation rates in SNpc
was found among patients destined to develop freezing
of gait early in PD [25]. This study, however, was limited
by a small sample size (n = 19), requiring validation in a
larger cohort.
Visualization of early changes in SN morphology using
MRI may emerge as a promising diagnostic biomarker
for PD. The SN is subdivided into pars compacta andpars reticulata, where the former contains a high density
of neuromelanin (NM) containing dopaminergic cells.
Using immunostaining for calbindin D28K, Damier et al.
delineated calbindin-negative pockets/zones within the
SNpc called 'nigrosomes' [26]. The greatest loss (~98%)
of NM containing dopaminergic neurons was identified
within a zone located in the caudal and medio-lateral
SN labelled as 'nigrosome-1'– the largest of the five
nigrosomes [27]. Accordingly, histological findings of
healthy nigrosome-1 found high tyrosine hydroxylase,
high NM, and low calbindin contents [28], while post-
mortem imaging at 7T identified healthy nigrosome-1 as
a hyperintense structure both on T2* and NM-sensitive
T1 MRIs due to its low iron and high NM contents, re-
spectively [28, 29]. In PD, however, this feature on 7T
(and 3T) MRIs was virtually absent or significantly re-
duced possibly due to decreased NM or increased iron
content, potentially providing a simple and specific diag-
nostic biomarker for PD [28–30]. Nigrosome-1 in PD
was histologically found to be low in tyrosine hydroxy-
lase and NM, consistent with the loss of melanized neu-
rons in SNpc [28, 29]. Using automated volumetry on
NM-sensitive 3T MRI, Castellanos et al. showed atrophy
in the contralateral SNpc to have the highest sensitivity
(91%) and specificity (89%) for differentiating PD from
controls [30]. Similarly, using NM-sensitive 3T MRI,
reduced area and width of T1 high signal in SN distin-
guished early-stage PD from essential tremor patients
(sensitivity 66.7%, specificity 93.3%) [31]. Translating the
findings to SW imaging, the healthy nigrosome-1 and
surrounding neuroanatomy at the dorsolateral SN was
found to visually resemble the tail of a swallow bird (the
‘swallow-tail’ sign) at 3T. This feature was lost in PD
subjects and radiological assessments yielded a high
diagnostic accuracy for PD compared to controls [32].Structural MRI profiles of Lewy body spectrum disorders
Visible changes on conventional MRI are frequently
non-specific and variable in DLB and PDD. Using VBM,
a diffuse pattern of cortical atrophy involving temporal,
occipital, right frontal and left parietal was identified in
PDD versus normal controls [12]. When DLB and PDD
groups were contrasted using VBM, Beyer et al. ob-
served more prominent cortical reductions in temporal,
occipital and parietal lobes in DLB patients [33].
Conversely, Burton et al. detected no such volumetric
differences suggesting similar patterns of atrophy in the
two closely-related α-synucleinopathies [12]. These vari-
able findings may in part be attributable to pathological
heterogeneity commonly observed in these disorders,
such as the presence of concomitant AD pathology in
DLB [5]. Indeed, more severe α-synuclein pathology and
plaque burden were associated with progressively shorter
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ation in PDD [34].
In PDD versus PD, more pronounced GM atrophy
was identified in the occipital lobe and entorhinal
cortex [12, 35]. Although hippocampal volumes alone
may not differentiate between PD and PDD patients [35],
starting from larger to smaller volumes they were found
to be affected in a characteristic order: controls > PD >
PD-MCI/PDD >AD [36] – a pattern that aligns with
neuropathological evidence. The relative preservation of
hippocampus (versus AD) is a supportive feature of DLB
pathology, which has been incorporated into the DLB
diagnostic criteria [4]. Notably, smaller hippocampal vol-
umes may also be evident in DLB and even PD-MCI/PDD
patients with concomitant AD pathology. Other inves-
tigations find reduced caudate and putaminal volumes
in DLB and PD patients compared to AD and normal
controls, although these differences were reported in-
consistently [14, 37]. White matter (WM) hyperinten-
sities may also be more frequent in PDD and DLB
disorders (versus PD and controls), especially with
coexisting AD pathology [38].
PD-MCI patients show reduced thalamic, amygdala
and nucleus accumbens volumes compared to PD with-
out MCI [39, 40]. In a longitudinal study, greater rates
of cortical thinning were identified in PD-MCI patients
in the temporal, occipital, parietal and supplementary
motor area (SMA), relative to cognitively-stable PD and
controls [40]. Involvement of SMA has been suggested
as a specific biomarker of cognitive dysfunction in PD
[40, 41]; whereas, marked occipital atrophy may beFig. 1 MRI of a patient with a clinical diagnosis of Multiple System Atrophy-C
cruciform pontine T2 hyperintensity consistent with the ‘hot cross bun’ sign s
System Atrophy-C. Disproportionate atrophy of the pons and partially visualiz
cruciform T2 hyperintensity within the pons and middle cerebellar peduncles
hemispheric and vermian atrophy is also seen with ex vacuo dilatation of the
brainstem and cerebellar vermisassociated with the development of hallucinations in
PD-MCI patients [41]. Interestingly, Weintraub et al.
reported a baseline AD-type pattern of atrophy pre-
dictive of long-term cognitive decline, supporting the
involvement of hippocampus and parietotemporal cor-
tex in cognitive impairment in PD [42].
Structural MRI profiles of multiple system atrophy
Several MRI-based features have been identified in
MSA. In MSA-P, these characteristics on conventional
MRI include: atrophy of the putamen, middle cerebellar
peduncles (MCP), cerebellum, or pons; presence of a
bilateral T2-hyperintense rim bordering the dorsolateral
margins of the putamen (the ‘putaminal rim sign’); and
T2-putaminal hypointensity. In MSA-C, atrophy of the
putamen, MCP or pons may be evident, including the
T2-hyperintensity of pons (the ‘hot-cross-bun sign’;
Fig. 1a) [6]. T2-hyperintensity of MCP (the ‘MCP sign’;
Fig. 1b) may also be observed in MSA [43]. Putaminal
atrophy shows a high specificity (92.3%), but low sensi-
tivity (44.4%) for distinguishing MSA-P from PD [44].
Meta-analysis of six studies (although heterogeneous)
found putaminal volume to be significantly reduced in
MSA patients versus PD, which may be helpful in the
differential diagnosis [45]. Massey et al. found radio-
logical assessment of MRI to be more accurate than the
clinical diagnosis, and confirmed the ‘MCP sign’ and
‘hot-cross-bun sign’ as specific for MSA, albeit with a
lower sensitivity [43]. Recently, a study compared the
visual appearance of the ‘hot-cross-bun sign’ and showed
it to be relatively clearer and of higher visual quality on. a Axial proton density sequence at the level of the pons demonstrates
econdary to selective vulnerability of the pontocerebellar tract in Multiple
ed cerebellar hemispheres is also evident. b Axial FLAIR sequence with
(i.e., ‘Middle Cerebellar Peduncle sign’) with marked atrophy. Cerebellar
fourth ventricle. c Sagittal T1 sequence showing marked atrophy of the
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visual grade was comparable in possible and probable
MSA-C patients suggesting improved utility to sup-
port the diagnosis at earlier stages [46]. Another
study compared the T2 appearances of the ‘putaminal
rim sign’ and T2-putaminal hypointensities on a 3T scan-
ner and found these to be unhelpful in distinguishing
MSA-P, PD and controls [44]. However, a combination of
T2-putaminal hypointensity on gradient-echo sequence
together with putaminal atrophy improved the diagnostic
specificity of MSA-P to 98% (versus PD) and 95% (versus
PSP), without altering the sensitivity [47]. Combined ana-
lysis of biomarkers may better differentiate MSA-P from
PD and other atypical PS.
VBM and volumetric studies typically reveal striatoni-
gral or olivopontocerebellar involvement in MSA patients.
Schulz et al. identified volumetric loss in the striatum and
brainstem regions in MSA versus PD and controls,
although with considerable overlap with PSP patients [16].
Reduced cerebellar volume was a feature of both MSA-P
and MSA-C subgroups [16]. Discriminant analysis allowed
good separation of MSA from PD and controls in this
study; however, MSA subtypes could not be reliably distin-
guished from PSP [16]. VBM in MSA-P patients showed
GM loss in the left primary motor cortex (versus PD) and
left SMA (versus controls) suggesting sensorimotor circuit
involvement [48]. Similarly, Brenneis et al. detected cor-
tical loss in the primary and supplementary motor areas
as well as prefrontal and insular cortices bilaterally, with
subcortical involvement of striatum and midbrain regions
versus PD and controls [49]. In MSA patients with
dementia, significant cortical thinning in the parahip-
pocampal and lingual cortices was apparent versus
non-demented MSA subjects [50]. Pontine atrophy is
commonly observed in MSA [6, 43]; however, it is
suggested that reduction in the area of pons over
time may better discriminate MSA from PSP than
cross-sectional volumetric assessment [51].Fig. 2 MRI of a patient with a clinical diagnosis of Progressive Supranuclea
‘Hummingbird’ sign (box), while the axial T1 sequence on the right shows
Supranuclear PalsyIn a study applying a comprehensive quantitative MRI
protocol (R1, R2 and R2* mapping, magnetization
transfer and diffusion tensor imaging [DTI] tech-
niques), the bilateral R2* increase in putamen best
separated MSA-P patients from PD [52], consistent
with SW imaging results demonstrating higher iron
deposition in putamen versus PD [53].
Structural MRI profiles of progressive supranuclear palsy
Atrophy of the midbrain tegmentum and superior cere-
bellar peduncles (SCP) are frequently detected in PSP
patients, compared to PD, MSA-P, CBS and controls
[54, 55]. Numerous MRI-based features suggestive of
PSP have been identified, including a midbrain diameter
less than 17-mm, third-ventricle dilation, midbrain T2-
hyperintensity, midbrain atrophy relative to pons (the
‘hummingbird sign’; Fig. 2) and the atrophy of midbrain
tegmentum (the ‘morning glory sign’; Fig. 2). The hum-
mingbird and morning glory signs were highly specific,
but less sensitive than the clinical PSP diagnosis [43].
Compared with normal controls, PSP patients showed
volumetric reductions in the mean whole-brain, brain-
stem, midbrain, and frontal GM [56]. All measured ana-
tomical structures showed extensive overlap within the
normal range, although overlap in midbrain volumes
was considerably less on an individual basis [56]. VBM
analysis in PSP identified neurodegenerative changes
primarily in the midbrain, pons, thalamus and striatum
versus controls, with midbrain structures more atrophic
than those seen in CBS [54]. Other VBM studies of PSP
revealed widespread cortical reductions in the prefrontal,
frontal, insular, premotor and SMAs, as well as in the
hippocampus and parahippocampal gyrus relative to
controls. WM atrophy in PSP was detected in the pulvi-
nar, thalamic, collicular, mesencephalic and frontotem-
poral regions [57, 58]. Relative to PD and controls,
significant tissue loss in PSP was detected in the cerebral
peduncles and midbrain, with minimal involvement ofr Palsy. The image on the left is a sagittal T1 sequence showing the
the ‘Morning Glory’ sign (arrows) both features seen in Progressive
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Frontal and midbrain atrophy rates, however, were asso-
ciated with increasing executive and motor dysfunction
in PSP, respectively [60]. In a pathology-proven sample,
Joseph et al. revealed distinct patterns of atrophy in PSP
compared to CBD patients [61]. Midbrain and SCP atro-
phy strongly suggested PSP, while frontoparietal and pal-
lidum degeneration (without prominent midbrain
atrophy) was indicative of CBD [61]. Interestingly, PSP
patients with prominent extrapyramidal symptoms may
show more midbrain atrophy. Conversely, less midbrain
and more cortical/subcortical atrophy was found in PSP
patients with dementia [61].
Ratios of the pons-to-midbrain area (P/M) and MCP-
to-SCP widths (M/S) were significantly larger in PSP pa-
tients, relative to PD, MSA-P and controls [62]. Remark-
ably, the ‘magnetic resonance (MR) parkinsonism index’
derived from P/M and M/S ratios, proved 100% sensitive
and specific for distinguishing PSP from PD, MSA-P and
healthy controls [62]. Recently, the utility of midbrain-to-
pons ratio was replicated in an autopsy-proven sample,
wherein all non-PSP patients showed a value of greater-
than 0.5 and the majority of PSP patients had a value less-
than 0.5 [63]. Whether this measure is helpful in distin-
guishing patients at very early clinically undifferentiated
stages, or in patients with PSP variants (e.g. PSP-P) where
midbrain involvement may be less pronounced, is un-
known. The midbrain atrophy rate predicts clinical decline
over as short a time interval as 6 months, which may have
potential as an effective outcome measure in PSP clinical
trials [64].
Structural MRI profiles of corticobasal degeneration
Asymmetric atrophy of the frontoparietal cortices is
typically observed in CBS/CBD patients contralateral to
the more affected side of the body, although laterality
may not exist in all cases (parietal > frontal atrophy in
pathologically proven CBD case; Fig. 3). Using VBM, an
asymmetric pattern of atrophy affecting the bilateralFig. 3 MRI of a patient with a pathological diagnosis of Corticobasal Degene
parietofrontal atrophy typical of that seen in Corticobasal Syndrome. In this ca
Degenerationpremotor cortex, superior parietal lobules, and striatum
was detected in CBS versus controls [54]. Dorsofrontal
and parietal cortical atrophy was found to be more pro-
nounced in CBS versus PSP [54]. Similarly, Gröschel
et al. reported parietal GM and WM to be significantly
reduced in CBS compared to PSP and controls [56].
Another VBM study in early CBS subjects detected GM
loss in the inferior frontal and premotor cortices,
parietal operculum, superior temporal gyrus, and the
hippocampus versus controls [65]. Parietal atrophy
correlated with limb apraxia in this study [65]. Signal
hyperintensities in the frontoparietal subcortical WM on
T2/FLAIR images may also be present, although these
changes are not consistently reported or specific to CBS.
Notably, all of the above studies were conducted in
samples that lacked pathological confirmation. Due to
low diagnostic sensitivity in CBS [9], research in
autopsy-proven samples may produce more precise re-
sults and are discussed below.
In an autopsy-proven sample, the degree of global
atrophy on gross pathology was visibly more severe in
CBD versus PSP [66] – a finding in line with MRI stud-
ies. Furthermore, the application of a pathological FTD
staging scheme noted that the pattern of tissue loss in
CBD was similar to other FTD-related tauopathies, while
greater posterior corpus callosum degeneration was evi-
dent in CBD cases relative to FTD [66]. In another
autopsy-proven sample of CBD patients clinically-
diagnosed with CBS, Joseph et al. concluded that cortical
atrophy, corpus callosum atrophy or periventricular
WM changes on MRI do not demonstrate specificity for
CBD [67]. Similarly, Whitwell et al. showed that the
pattern of GM loss in CBS varies based on the true
underlying pathology. In clinically-diagnosed CBS pa-
tients with pathologic diagnoses of FTD and AD, the
GM loss was predominantly observed in the prefrontal
cortex and parietal lobe, respectively [11]. Furthermore,
focal loss in the premotor cortex and SMA was seen in
both CBD and PSP patients, although more severeration. Serial axial T1 sequences showing right greater than left
se, the patient had a confirmed pathological diagnosis of Corticobasal
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[11]. Using VBM in an autopsy-proven CBD sample, Lee
et al. confirmed GM loss in the bilateral frontal cortex
(including SMA), dorsolateral prefrontal cortex, pre- and
post-central gyri, striatum, and brainstem, as compared
to controls [68]. CBD can also present as a predominant
extrapyramidal or cognitive syndrome. Cortical loss pre-
dominantly in the frontal lobes and insula with scarce
WM atrophy was found in CBD with early dementia,
whereas only moderate loss in these regions involving
both GM and WM was evident in CBD with early extra-
pyramidal manifestations [61]. Thus, not unexpectedly,
variable patterns of atrophy in CBD appear to corres-
pond to the predominant clinical syndrome rather than
the underlying cellular pathology.
Diffusion tensor magnetic resonance imaging in
Parkinsonian disorders
Diffusion tensor imaging is an in vivo tractography tech-
nique that allows indirect quantification of brain micro-
structural integrity by analyzing the overall displacement
of water molecules (mean diffusivity [D̄]) and the degree
of displacement in space (fractional anisotropy [FA]). In
brain, water tends to move preferentially along the
underlying microstructural WM tracts and this physical
property can be used to measure D̄ and FA, using voxel-
based or region-of-interest approaches. Degeneration of
WM tracts increases D̄ while FA decreases, as the
direction-dependent movement of water along the
damaged tracts becomes restricted.
Decreased FA in the SN is commonly observed in PD
patients, although its association with disease severity is
unclear [69]. Using high-resolution DTI, greater FA
reductions in caudal (than in middle or rostral) regions
of the SN were identified, distinguishing PD from con-
trols with 100% sensitivity and specificity [70]. Increased
D̄ in olfactory tracts and decreased FA in anterior olfac-
tory structures have also been reported [71, 72], which
are in line with olfactory disturbances seen in PD pa-
tients. Some studies find no measurable differences in D̄
or FA in early PD versus normal subjects, possibly due
to milder degenerative changes at early stages [73].
Atypical PS, as a group, may be distinguishable from PD
by measuring increased D̄ primarily in the corpus callo-
sum, putamen, midbrain, as well as superior cerebellum
and cerebellar peduncles [74].
In MSA-P, an elevated putaminal D̄ was identified
relative to PD, MSA-C and healthy controls [74, 75].
Remarkably, a combination of increased T2* relaxation
rates and D̄ in the putamen enabled discrimination of
PD from MSA-P patients with 96% accuracy [75]. Like-
wise, Ito et al. found lower FA and increased apparent
diffusion coefficient (ADC) values in MSA-P patients in
putamen, cerebellum and pons, versus PD and controls[76]. FA and ADC in the pons proved to be highly
specific (100%) for differentiating MSA-P patients from
PD, and it was concluded that a combined analysis of
pons, putamen and cerebellum might be more discrim-
inatory than single-region analysis [76]. FA values in the
corpus callosum and SCP did not differ between MSA
and controls [77], whereas FA was markedly reduced in
the MCP region versus PSP and controls [77, 78], correl-
ating inversely with ataxia severity in MSA patients [77].
Cerebellar ataxia also correlated with elevated D̄ values
in the MCP and pons [78]. Marked FA decline was
noted in the MCP, inferior cerebellar peduncle, and ven-
tral pons among the MSA-C subjects versus controls
[79]. Pellecchia et al. compared tractographic changes in
MSA variants and reported increased ADC values in the
putamen and pons in MSA-P (versus MSA-C and
controls), and in the cerebellum and MCP in MSA-C
subjects (versus MSA-P and controls), which may be
helpful as biomarkers of microstructural injury in these
disorders [80].
Compared with healthy subjects, DTI studies in PSP pa-
tients may show: increased D̄ or ADC in the decussation
of SCP, thalamus, cingulum, motor and SMA [78, 81];
decreased FA and increased ADC in the frontal part of
inferior frontooccipital fasciculus [82]; and decreased FA
in the orbitofrontal WM, anterior cingulum and motor
area [81], as well as in the superior longitudinal fasciculus,
arcuate fasciculus, posterior thalamic radiations and in-
ternal capsule [58]. Elevated D̄ in the midbrain and SCP
distinguished PSP from other atypical PS [74]. Blain et al.
reported increased D̄ in the decussation of SCP in PSP
compared to MSA, PD and controls [78]. Seppi et al. also
found raised ADC values in the putamen, globus pallidus
and caudate nucleus, which discriminated PSP from PD
(sensitivity 90%, specificity 100%) [83]. Using serial MRIs
two years apart from each other, a significant increase in
putaminal ADC was detected in PSP versus controls (with
no measurable change in MSA patients), suggesting
putaminal changes over time as a potential differentiating
biomarker [51].
In CBS relative to controls, decreased FA was identified
in the long frontoparietal connecting tracts, intraparietal
associative fibers, corpus callosum and sensorimotor cor-
tical projections [65]. FA abnormalities in frontoparietal
associative fibers correlated with limb apraxia, while the
limb-kinetic measure of apraxia correlated with FA values
in the hand sensorimotor connecting fibers [65]. Corpus
callosum DTI abnormalities may be useful in differentiat-
ing CBS from PD, as increased D̄ and decreased FA were
observed in the posterior truncus of corpus callosum,
reflecting neurodegenerative changes in transcallosal con-
nectivity [73].
Relative to controls, DTI studies in DLB show abnor-
malities in the corpus callosum, dorsal striatum, frontal,
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amygdala and inferior longitudinal fasciculus with less
temporal involvement [85]. Conversely, AD patients
show reduced FA and elevated D̄ in the medial temporal
lobe structures (especially the hippocampus). Decreased
FA was detected in the precuneus in DLB versus AD
[86], and in the posterior cingulate bundles in PDD ver-
sus PD [87]. Elevated D̄ in the longitudinal fasciculus
was exclusively found in DLB patients with hallucina-
tions relative to DLB without hallucinations [85].
Proton magnetic resonance spectroscopy
Proton magnetic resonance spectroscopy (1H-MRS) is a
non-invasive in vivo imaging technique that relies upon
the resonance frequencies of protons to estimate the
amount of biochemical molecules in brain. The relative
concentrations of proton-containing metabolites appear
as peaks on a neurospectrograph near their characteris-
tic resonance frequencies. Using MRS, the following me-
tabolites are commonly assessed in neurodegenerative
disorders: (a) N-acetyl aspartate (NAA) – an indicator of
neuronal health, integrity and metabolism; (b) Choline-
containing compounds, primarily free choline, phosphor-
ylcholine and glycerophosphorylcholine – markers of
membrane turnover, osmoregulation and inflammation;
(c) myo-inositol – a signature of gliosis, demyelination
and osmoregulation, and (d) Creatine (Cr), mix of creatine
and phosphocreatine – a reference standard with relatively
stable levels in healthy brain and is used to normalize the
spectral data for comparative purposes [88].
In PD, reduced NAA or NAA/Cr levels were observed in
the lentiform nucleus (LN) (putamen and globus pallidus),
temporoparietal and posterior cingulate cortex as well as
in the pre-SMA relative to normal controls [88–91]. There
have been inconsistent reports of a correlation between
NAA/Cr ratios in these regions with disease severity or
duration [88–91]. Using 3D MRS, Gröger et al. noted
higher NAA/Cr ratio in the rostral (versus caudal) SN in
atypical PS and controls, whereas this pattern was reversed
in PD suggesting pathological neuronal loss in the rostral
SNpc [92]. PSP patients showed reductions in NAA/Cr ra-
tios in the LN, brainstem, centrum semiovale, frontal and
pre-central regions relative to controls [93, 94], although
more severe reductions were noted in the putamen (versus
PD and MSA) [86] and frontal cortex (versus PD) [88, 95].
Lower NAA/Cr ratios were also noted in the putamen
and pontine base in MSA patients compared to PD
and controls [96]. CBS subjects showed reductions in
NAA/Choline or NAA/Cr levels in the frontoparietal
cortex, LN and centrum semiovale contralateral to
the more affected side [94, 97]. NAA/Cr reductions
in CBS were pronounced in the frontal cortex and
putamen relative to PD, MSA and vascular parkinson-
ism with clear putaminal asymmetry [95]. Notably,lower NAA/Cr values in the putamen are found in
PSP subjects as well, and laterality observed in CBS
may be helpful in differentiating the two disorders
(although, this may simply affirm what is apparent on
clinical examination). In fact, putaminal NAA levels
were found to be reduced across PD, MSA, PSP and
CBS patients versus controls, although to varying de-
grees within each of these parkinsonian syndromes.
Patients with DLB and PDD may exhibit lower NAA/
Cr values in the posterior cingulate gyrus and medial
temporal lobe structures, but to a lesser degree than
in AD [98, 99].
In a recent study, Mazuel et al. showed restoration
of total NAA and Cr levels in putamen with no
change in total myo-inositol levels in PD patients
undergoing L-DOPA treatment. The total NAA, Cr
and myo-inositol levels were lower in these patients
in the off-drug condition versus normal controls
[100]. Another study found an association between
parkinsonism severity (via Hoehn and Yahr staging)
and putaminal NAA/Cr ratios in atypical PS patients
(Table 1) [95].
Single photon emission computed tomography in
Parkinsonian disorders
SPECT is a functional nuclear imaging technique pre-
dominantly used in PS to assess the integrity of nigros-
triatal dopaminergic system as well as to detect cerebral
perfusion changes in vivo. SPECT employs selective
gamma-emitting cocaine analogues, such as 123I-N-ω-
fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl) nortro-
pane (123I-FP-CIT or 123I-ioflupane), which bind to striatal
dopamine transporters (DAT), as well as ligands for dopa-
mine D2 receptors, such as 123I-(S)-(−)-2-hydroxy-3-iodo-
6-methoxy-N-([1-ethyl-2-pyrrolidyl]-methyl) benzamide)
(123I-IBZM). DAT is a sodium-coupled transmembrane
protein that mediates the reuptake of dopamine from the
synaptic cleft, and is localized to presynaptic nigrostriatal
terminals. Striatal dopamine D2 receptors are G-protein-
coupled inhibitory receptors expressed both at the
dopamine target cells postsynaptically, as well as pre-
synaptically on the nigrostriatal axonal terminals
[101]. SPECT-based imaging of dopamine D2 receptors
evaluates the post-synaptic functioning of striatal neurons.
123I-FP-CIT is the most widely utilized ligand to measure
DAT density due to its faster kinetics, greater selectivity
and compatibility with levodopa treatment. Cerebral
perfusion changes can be measured via SPECT using
lipophilic radiotracers, such as 99mTc-ethyl-cysteinate-di-
ethyl-ester (99mTc-ECD) and 99mTc-hexamethyl-propyl-
ene-amine-oxime (99mTc-HMPAO), which can traverse
the blood-brain barrier, perfuse brain tissues, and therefore
their uptake is proportional to cerebral blood flow
(Table 2).
Table 1 Common magnetic resonance imaging findings in Parkinson’s disease and atypical parkinsonian syndromes
Neuropathology Disorders MRI signs Structural/volumetric MRI findings Diffusion Tensor MRI
findings
Proton MRS findings
Synucleinopathies PD 1. Swallow tail sign
2. Loss of nigrosome-1
↓ in frontal lobe, hippocampus,
anterior cingulate and superior
temporal gyri, and olfactory bulb
and tract volumes vs. HC [12, 13, 17]
↓ in orbitofrontal, ventrolateral,
prefrontal and occipitoparietal cortex
vs. HC [15]
○ or ↓ in caudate, putamen and
brainstem volumes vs. HC [14–16]
↑ R2* transverse relaxation rate in SN
vs. HC [19, 25]
DTI may be normal in
early-PD vs. HC [73].
↓ FA in SN and anterior
olfactory structures; and
↑ D̄ in olfactory bulb and
tracts vs. HC [69–72].














↓ in temporal, occipital, frontal
and parietal cortices in PDD vs. HC
[12, 27].
↓ in temporal, occipital and parietal
cortices may be seen in DLB vs. PDD
[33]
↓ in occipital and entorhinal cortices
in PDD vs. PD [12, 35].
↓ in thalamic, amygdala and nucleus
accumbens volumes, and ↑ in rate of
temporal, occipital, parietal and SMA
cortical thinning in PD-MCI vs. PD-
non-MCI [39, 40]
↑ WM abnormalities in
corpus callosum, dorsal
striatum, frontal, parietal
and occipital regions, as
well as in amygdala and
inferior longitudinal
fasciculus in DLB with less
temporal involvement vs.
HC [84, 85].
↓ FA in parietal lobe
(precuneus) in DLB vs.
AD [86].
↓ in NAA/Cr values in the
posterior cingulate gyrus
and medial temporal lobe
structures in DLB and
PDD, although to a lesser
degree than in AD [98, 99].
MSA 1. Putaminal rim sign
2. Hot-cross-bun sign
3. MCP sign
↓ in putamen, MCP, cerebellum,
pons and striatal volumes in MSA-P
and MSA-C vs. HC [6, 16].
↓ in putaminal, cerebellar and
pontine volumes in MSA
vs. PD [16, 44, 45]
↓ in primary and SMA, prefrontal and
insular cortices, striatum and
midbrain in MSA-P vs.
PD and HC [49]
↑ cortical thinning in
parahippocampal and lingual cortex
in MSA-demented vs. MSA-non-
demented [50]
↑ putaminal D̄ in
MSA-P vs. PD, MSA-C
and HC [74, 75].
↓ FA and ↑ ADC in MSA-P
in putamen, cerebellum and
pons vs. PD and HC [76].
↓ FA in MCP, inferior
cerebellar peduncle, and
ventral pons in MSA-C vs.
HC [79].
↓ FA and ↑D̄ in MCP and
pons vs. HC [77, 80].
↑ ADC in cerebellum and
MCP in MSA-C vs. MSA-P
and HC [80]; ↓ FA in MCP
vs. PSP and HC [77, 78]
↓ in NAA/Cr ratio in
putamen and pontine
base in MSA vs. PD and
HC [96].
Tauopathies PSP 1. Hummingbird sign
2. Morning glory sign
↓ in prefrontal, frontal, insular,
premotor, SMA, hippocampus and
parahippocampal regions; ↓ WM in
pulvinar, thalamus, colliculus,
mesencephalon and frontotemporal
regions; ↓ in midbrain, pons,
thalamus and striatum, vs. HC
[57, 58].
↓ in midbrain and SCP volumes vs. PD,
MSA-P, CBS and HC [54, 55, 59, 61, 62]
↓ in brainstem, midbrain and frontal
cortex vs. HC [56]
↓ midbrain atrophy and ↑ cortical/
subcortical atrophy in PSP with
dementia [61]
↑ D̄ or ADC in
decussation of SCP,
thalamus, cingulum,









cingulum, motor area vs.
HC [58, 78, 81, 82]
↑ ADC in putamen and
pons in MSA-P vs. MSA-C
and HC [80]
↓ in NAA/Cr ratio in LN,
brainstem, centrum
semiovale, frontal and
precentral cortex vs. HC
[93, 94].
Relatively greater ↓ in
NAA/Cr ratio in putamen
and frontal cortex vs. PD
[86, 88, 95].
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Table 1 Common magnetic resonance imaging findings in Parkinson’s disease and atypical parkinsonian syndromes (Continued)
↑ D̄ in midbrain and SCP
vs. atypical PS group [74].
↑ ADC in putamen,
globus pallidus and
caudate nucleus vs. PD
[83].
CBD/CBS ↑ global brain atrophy in CBD vs.
PSP [66]
↓ in bilateral frontal cortex (including
SMA), dorsolateral prefrontal cortex,
pre/post-central gyri, striatum, and
brainstem in CBD vs. HC [68]
↓ in frontal and insula cortex with
scarce WM atrophy in CBD-dementia;
moderate ↓ in GM/WM of these
regions in CBD with early
extrapyramidal manifestations [61]
↓ in prefrontal cortex and parietal
lobe, respectively, in CBD-FTD and
CBD-AD [11]






of cortical hand areas, in
CBS vs. HC [65].









putamen, in CBS vs. HC
[94, 95, 97].
Greater ↓ in NAA and
NAA/Cr levels in frontal
cortex and putamen with
marked putaminal
asymmetry, in CBS vs. PD,
MSA and vascular
parkinsonism [95]
Legend: ○ normal; ↓ decrease; ↑ increase
Abbreviations: AD, Alzheimer’s disease; ADC, apparent diffusion coefficient; CBD, pathologically-proven corticobasal degeneration; CBS, clinically-diagnosed
corticobasal syndrome; D̄, mean diffusivity; DLB, dementia with Lewy bodies; DTI, diffusion-tensor imaging; FA, fractional anisotropy; FTD, frontotemporal
degeneration; HC, healthy controls; LBD, Lewy body spectrum disorders; LN, lentiform nucleus; MCI, mild cognitive impairment; MCP, middle cerebellar peduncle;
MRS, magnetic resonance spectroscopy; MSA, multiple system atrophy; MSA-P, MSA-parkinsonian type; MSA-C, MSA-cerebellar type; NAA, N-acetyl aspartate; NAA/
Cr, NAA-to-creatine ratio; PD, Parkinson’s disease; PDD, Parkinson’s disease dementia; PS, parkinsonian syndromes; PSP, progressive supranuclear palsy; SCP,
superior cerebellar peduncle; SMA, supplementary motor area; SN, substantia nigra; WM, white matter
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Imaging presynaptic DAT with SPECT (DAT-SPECT)
has been investigated for its utility in the differential
diagnosis of PS. Normal DAT binding using 123I-FP-CIT
appears as two intense symmetric ‘comma-shaped’ re-
gions of activity in the striatum (caudate anteriorly and
putamen posteriorly); whereas, an abnormal scan may
fall into one of four types: (a) asymmetrically reduced
putaminal activity, (b) symmetrically reduced putaminal
activity with relative preservation of caudate activity, (c)
virtual absence of putaminal activity associated with
reduced caudate activity unilaterally or bilaterally, and
(d) fairly uniform involvement of putamen and caudate
unilaterally or bilaterally [102, 103]. SPECT shows
normal density of presynaptic DAT in healthy controls,
patients with essential tremor and in drug-induced or
psychogenic parkinsonism [104–106], whereas reduced
DAT uptake is indicative of nigrostriatal degeneration
and is detected in PD, PDD, MSA and PSP patients
versus controls [105, 107, 108]. DAT binding was also
significantly impaired in DLB and PD patients versus
AD and controls [109, 110]. Loss of DAT is typically
more pronounced in the hemisphere contralateral to the
parkinsonian symptoms/signs and tends to appear sym-
metric in patients with symmetric motor deficits [111].
The posterior putamen shows earlier and more severe
signal loss than the anterior putamen or caudate in PD
[111]. Significant correlations of striatal DAT-SPECTbinding with the Hoehn & Yahr disease stage, UPDRS
motor score, and with the UPDRS bradykinesia subscale
have been demonstrated, although no associations with
rigidity or tremor were observed [104, 112–114].
A meta-analysis confirmed the utility of DAT-SPECT
for the differential diagnosis of early PD from healthy con-
trols, patients with essential tremor, and vascular parkin-
sonism with high accuracy [115]. A multi-centered study
evaluating the utility of visual assessment of 123I-FP-CIT
SPECT reported a sensitivity of 97% for clinically-
diagnosing parkinsonism and a specificity of 100% for reli-
ably excluding essential tremor cases across institutions
[116]. In a longitudinal study, Nocker et al. reported
higher rates of signal reductions in the caudate and anter-
ior putamen in MSA-P patients relative to PD – a finding
consistent with faster rate of disease progression in MSA-
P [117].
Several investigations suggest a different pattern of DAT
loss in PSP. In contrast to PD and MSA-P, a more sym-
metric pattern of DAT loss was observed [104, 118, 119],
with an index of asymmetry significantly higher in PD
than in PSP [119]. Lower striatal-to-occipital, but higher
putamen-to-caudate binding ratios were found in PSP
versus PD [118, 119], indicating a relatively uniform
involvement of striatal dopamine neurons in PSP. Using
123I-N-(3-iodopropen-2-yl)-2β-carbomethoxy-3β-(4-chlor-
ophenyl) tropane (123I-IPT), Im et al. confirmed that PSP
patients exhibit more pronounced but fairly uniform DAT
Table 2 Common radionuclides used in SPECT, PET and myocardial scintigraphy imaging
Radionuclide IUPAC name Main Target or Measure
SPECT
Nigrostriatal Integrity
123I-FP-CIT (123I-ioflupane) 123I-N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane Presynaptic DAT
123I-β-CIT 123I-2β-carbomethoxy-3β-(4-iodophenyl)tropane Presynaptic DAT
123I-IPT 123I-N-(3-iodopropen-2-yl)-2β-carbomethoxy-3β-(4-chlorophenyl)tropane Presynaptic DAT










123I-epidepride 123I-(S)-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-iodo-2,3-dimethoxybenzamide Postsynaptic D2 receptors
Cerebral Perfusion
99mTc-ECD 99mTc-ethyl cysteinate diethylester Cerebral perfusion
99mTc-HMPAO 99mTc-hexamethylpropyleneamineoxime Cerebral perfusion
123I-IMP 123I-N-isopropyl-p-iodoamphetamine Cerebral perfusion
PET
Nigrostriatal Integrity




11C/18F-β-CFT 11C/18F-2-β-carbomethoxy-3-β-(4-fluorophenyl)tropane Presynaptic DAT
11C-methylphenidate 11C-methylphenidate Presynaptic DAT
11C/18F-DTBZ 11C/18F-dihydrotetrabenazine Presynaptic VMAT2





11C-PIB 2-(4-N-11C-methylaminophenyl)-6-hydroxybenzothiazole Cerebral amyloid
18F-florbetaben 4-{(E)-2-[4-(2-{2-[2-18F-Fluoroethoxy]ethoxy}ethoxy)phenyl]vinyl}-N-methylaniline Cerebral amyloid
Cerebral Tau
18F-T807 (18F-AV-1451) 7-(6-fluoropyridin-3-yl)-5H-pyrido[4,3-b]indole Cerebral tau
18F-FDDNP 2-(1-(6-[(2-18F-fluoroethyl)(methyl)amino]-2-naphthyl)ethylidene)malononitrile Cerebral tau
18F-THK523 2-(4-aminophenyl)-6-(2-18F-fluoroethoxy)quinoline Cerebral tau





18F-FDG 18F-fluoro-2-deoxyglucose Glucose metabolism
Neuroinflammation






123I-MIBG 123I-metaiodobenzylguanidine Cardiovascular dysautonomia
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parison, PD patients demonstrated lower DAT reductions
(or higher signal) in the caudate head and caudate/puta-
men transitional region relative to putamen, with smaller
posterior putamen-to-caudate binding ratios [107].
Despite these findings, the pattern of striatal DAT loss has
not proven reliable in differentiating parkinsonian disor-
ders on an individual case basis.
DAT-SPECT has a useful role in distinguishing DLB
from other forms of dementia in uncertain cases.
Abnormal DAT scan in patients clinically-diagnosed as
‘possible’ DLB suggests a revised diagnosis to ‘probable’
DLB at a 12-month follow-up [120]. Using 123I-FP-CIT,
a longitudinal study with neuropathological confirmation
reported 88% sensitivity and 100% specificity of diagnosing
DLB versus AD – accuracy superior than clinical diagnosis
alone (sensitivity 75%, specificity 42%) [121]. A meta-
analysis evaluating both visual and semi-quantitative
studies supported these findings showing sensitivity and
specificity of 123I-FP-CIT to be greater than 80% in differ-
entiating DLB from other dementia syndromes of AD and
FTD. These values greatly improved when neuropatho-
logical diagnosis was used as a reference standard (sensi-
tivity 87%, specificity 92%) [122]. These results suggest
that the clinical diagnosis of DLB can be improved upon
using 123I-FP-CIT SPECT. Another meta-analysis
reported similar accuracies in differentiating DLB from a
non-DLB group (sensitivity 86.5%, specificity 93.6%),
although studies employing different analytic and diagnos-
tic methodologies were pooled and assessed together in
this analysis [123]. Finally, CBS patients showed DAT
reductions in the striatum, but with greater hemispheric
asymmetry than in PD [124, 125]. In a study of two
pathologically-proven CBD cases, asymmetry of DAT loss
was found to be significantly worse on follow-up scan and
maybe of diagnostic value in possible CBD patients [125].
Interestingly, about 10-20% of PD patients, enrolled in
neuroprotective trials of PD undergoing DAT imaging,
were found to have ‘scans without evidence of dopamin-
ergic deficit’ (acronym: SWEDD) [126]. Follow-up studies
so far have established SWEDD as a relatively heteroge-
neous group, with the following main conclusions: 1) most
cases represented a clinical misdiagnosis of PD (com-
monly dystonia), 2) some cases were false-negatives with
true PD, as evidenced by abnormal follow-up scan and a
positive levodopa response, 3) initial imaging reports may
have been inaccurate in some due to practical/methodo-
logical issues, and 4) accurate diagnoses in many cases
remains unclear due to lack of neuropathological confirm-
ation [126–128].
Postsynaptic dopamine D2 receptor imaging
Using SPECT with 123I-IBZM and 123I-(S)-5-iodo-7-N-
[(1-ethyl-2-pyrrolidinyl) methyl] carboxamido-2,3-dihydrobenzofuran (123I-IBF) as ligands, binding poten-
tials for postsynaptic D2 receptors were identified to be
within the normal range in levodopa-treated PD as well
as in patients with essential tremor and DLB [105, 111].
Conversely, reduced binding potentials were detected
among MSA and PSP patients versus controls [105,
129]. Striatal D2 receptors were upregulated in drug-
naïve PD patients, likely in response to nigrostriatal
denervation with the greatest increase in the posterior
putamen [111, 130]. Studies generally find the density of
D2 receptors to be preserved among CBS patients,
although this finding was not reliably shown on an indi-
vidual case-to-case basis. Using 123I-IBZM as a tracer,
Klaffke et al. [108], Pirker at al. [131] and Plotkin at al.
[105] respectively reported 7 out of 8 (7/8), 8/9 and 7/9
clinically-diagnosed CBS patients with normal D2 bind-
ings, suggesting preservation of dopamine D2 receptors.
It is important to consider that a normal D2 SPECT scan
may not exclusively confirm or discount an atypical PS.
Further studies with pathologically-proven samples are
warranted to determine the true sensitivity and specifi-
city of D2 SPECT in distinguishing atypical PS.
Striatal region-of-interest analysis using D2 SPECT
ligands revealed that the ratios of posterior putamen to
caudate binding were > 1 in almost all drug-naïve PD
cases, levodopa-treated PD and PSP patients. In con-
trast, this ratio was < 1 in 5/7 MSA patients, implicating
a more pronounced loss of D2 receptors in the posterior
putamen of MSA individuals [111]. Further research is
necessary to clarify and better understand the role of D2
receptor binding in the differential diagnosis of PS.
Some studies examined the utility of combining pre-
synaptic DAT imaging with postsynaptic D2 receptor
SPECT in an effort to improve the diagnostic accuracy.
A meta-analysis, however, reported the diagnostic accur-
acy of SPECT using both pre- and postsynaptic tracers
to be relatively low [115]. Koch et al., on the other hand,
demonstrated a gain of diagnostic power using a dual
tracer model that integrated both striatal 123I-IBZM D2
receptor binding together with presynaptic DAT
imaging via 123I-FP-CIT. This model discriminated
PD from atypical PS with 90.3% sensitivity and 73.9%
specificity, superior than using striatal D2 receptor
binding alone [132].
Cerebral perfusion studies
Using 99mTc-HMPAO as a tracer in DLB, regional hypo-
perfusion was detected in the parietal, temporal and
occipital regions relative to controls [133]. Upon com-
parison with AD, occipital hypoperfusion in DLB
patients was the only differentiating feature in this study
[133]. Occipital hypoperfusion in DLB patients has also
been observed using other tracers, including N-isopro-
pyl-p-123I-iodoamphetamine (123I-IMP), and 99mTc-ECD.
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frontal lobe and occipital cortex versus controls [134,
135], whereas increased perfusion was detected in the
primary sensorimotor cortex [136]. This frontal lobe
hypoperfusion was also evident in a one-year follow-up
study in PD [137]. Song et al. compared PD and MSA-P
subjects using 123I-IMP tracer and reported frontal cor-
tex hypoperfusion in both disorders, although occipital
hypoperfusion was exclusive to PD [136]. Conversely,
putaminal hypoperfusion was evident in MSA-P patients
relative to PD [136]. Decreased perfusion in PDD (versus
controls) was found in all cortical areas, particularly the
temporal and parietal regions [135]. In MSA-C patients,
hypoperfusion together with local atrophy was detected
in the cerebellum and pons compared to controls [138].
Positron emission tomography in Parkinsonian
disorders
Positron emission tomography (PET) is another in vivo
functional neuroimaging technique that utilizes a variety
of radionuclides to elucidate the integrity of the dopa-
minergic system, cerebral metabolism, pathological
protein accumulation, and inflammation in the brain.
Radiotracers, such as 18F-dopa and 11C-raclopride, can
be employed to image the integrity of presynaptic and
postsynaptic nigrostriatal projections, respectively. The
functioning of the pre-synaptic monoaminergic system
can be evaluated using 11C-dihydrotetrabenazine (11C-
DTBZ) or 18F-labelled analogues. Cerebral glucose
metabolism is commonly assessed using 18F-labelled
fluorodeoxyglucose (18F-FDG) tracer, where reduced
uptake is suggestive of lower regional tissue metabol-
ism. Amyloid burden in the brain has been widely
assessed using an 11C-labelled thioflavin analogue,
known as the Pittsburgh compound B (11C-PIB), as
well as using other 18F-labelled ligands. Finally, tau
imaging is a newer technique that is still in its in-
fancy and is aimed at detecting abnormally-folded tau
deposits in AD and other tauopathies.
Presynaptic and postsynaptic dopaminergic imaging
Imaging the nigrostriatal dopaminergic system using
PET provides helpful diagnostic information and com-
plements SPECT findings. 18F-dopa is a well-known
presynaptic PET tracer that measures the density of pre-
synaptic nigrostriatal axons, specifically, the activity of
the nigrostriatal aromatic amino acid decarboxylase
(AADC) protein – an enzyme that converts 18F-dopa to
18F-dopamine, and provides an indirect estimation of the
dopaminergic storage pool. In PD, a decrease in 18F-
dopa uptake is first observed in the posterior putamen,
followed by the anterior putamen and caudate nucleus,
contralateral to the clinically affected side [139, 140].
Striatal 18F-dopa uptake was found to be associated withPD progression, while putaminal 18F-dopa uptake (but
not caudate nucleus) showed an association with motor
severity [140]. 18F-dopa activity was also reduced in pu-
tamen in atypical PS versus controls [141–143], but with
a more severe decline in the caudate head relative to PD
[142]. Similarly, Brooks et al. detected depressed striatal
18F-dopa uptake in PD, PSP and MSA versus controls
[141]. In contrast to PD, however, putamen and caudate
regions were equally impaired in PSP, and the mean up-
takes in these regions among MSA patients were in be-
tween that of PD and PSP [141]. Similar to DAT-SPECT
findings, striatal DAT PET studies have also found ab-
normal uptake in PD, MSA-P, PSP and DLB groups ver-
sus controls, whereas normal activity was detected in
patients with essential tremor and MSA-C [144, 145].
Using dual-phase 18F-FP-CIT PET, Jin et al. found that
visual interpretation of early-phase images (acquired at
5-min) to have a favourable diagnostic potential for dis-
tinguishing PD from atypical PS (sensitivity 75.4%, specifi-
city 100%) [144]. Using a recently-developed PET
radiotracer, 18F-(E)-N-(3-iodoprop-2-enyl)-2β-carbo-
fluoroethoxy-3β-(4′-methyl-phenyl)nortropane (18F-
FE-PE2I), reduction in DAT in the striatum and SN
was replicated in PD patients versus controls. A shorter
acquisition time (~22 min) and favorable kinetics were
emphasized as advantages of 18F-FE-PE2I compared to
traditional radionuclides [145]. Importantly, presynaptic
tracers may not precisely estimate the nigrostriatal dopa-
minergic injury due to ongoing compensatory mecha-
nisms, including the up-regulation of AADC activity
and down-regulation of presynaptic DAT in response
to neurodegeneration [146].
11C-DTBZ tracer or (its 18F-labelled analogues) labels
the vesicular monoamine transporter type-2 (VMAT2),
important for packaging and storing monoamines (e.g.
dopamine) into synaptic vesicles. 11C-DTBZ PET have
shown decreased striatal VMAT2 binding in PD reflect-
ing nigrostriatal degeneration, accompanied by rather
minimal compensatory changes [146]. Conversely, the
binding potential for 11C-methylphenidate (DAT ligand)
was reduced to a much greater extent relative to 11C-
DTBZ, suggesting marked compensatory down-
regulation of striatal DAT activity [146]. Using a novel
18F-tetrabenazine derivative [18F-FP-(+)-DTBZ or 18F-
AV-133], Okamura et al. detected the greatest regional
decrease in VMAT2 binding in the posterior putamen,
followed by anterior putamen and caudate nucleus in
PD [147].
11C-raclopride is a PET tracer that binds to striatal
post-synaptic D2 receptors. In untreated PD patients,
D2 binding potentials may appear normal or upregulated
contralateral to the clinically affected side versus controls
[148–150], whereas, reductions are more commonly seen
in medicated PD [148], as well as in atypical PS patients
Saeed et al. Translational Neurodegeneration  (2017) 6:8 Page 15 of 25[150]. Reduced 11C-raclopride binding differentiated all
medicated PD patients from healthy controls [151].
Binding was found to be reduced in PSP patients (versus
controls) [150], and MSA patients (versus PD and con-
trols) [143, 151], which correlated with striatal glucose
hypometabolism in MSA [151]. Van Laere et al. con-
trasted 11C-raclopride binding potentials in MSA-P and
PD subjects, and identified the caudate-to-putamen and
anterior-to-posterior putamen binding potential ratios to
be significantly higher in MSA-P patients than in PD
[152]. Consistent with striatal D2 SPECT studies [111],
this result suggests bilateral D2 receptor loss in putamen
of MSA-P patients, especially in the posterior part. Mean
11C-raclopride local influx ratios were also decreased in
the bilateral pons, bilateral cerebellum, and posterior pu-
tamen in MSA-P patients versus PD (albeit with extensive
overlap) – a finding consistent with brain volumetric,
perfusion and metabolic studies in MSA. Discriminant
analysis that combined 11C-raclopride striatal binding
potentials with local influx ratios improved discrimin-
ation between MSA-P and PD patients with 100%
accuracy (when normal controls were excluded from
the analysis) [152].Glucose metabolism
In PD, 18F-FDG-PET often reveals relatively preserved
glucose metabolism in the LN and thalamus [153, 154],
and hypometabolism in the bilateral parietal, premotor
and supplementary motor regions relative to controls
[153, 155]. This preserved metabolism in the basal
ganglia may distinguish PD patients from MSA and PSP,
where a corresponding metabolic decline is commonly
observed. MSA patients exhibit impaired glucose metab-
olism in the bilateral basal ganglia, putamen, pons and
cerebellum, compared to PD and controls [156, 157]. A
multimodal study combining FDG-PET with DTI
detected an elevated D̄ in posterior putamen of MSA-P
patients that corresponded with local reductions in FDG
metabolism [158], suggesting an association between pu-
taminal microstructural damage and related metabolic
dysfunction in the brain.
Relative to controls, PSP patients commonly show
glucose hypometabolism in the basal ganglia, midbrain,
anterior cingulate cortex, frontal lobe and primary
motor cortex [153, 157, 159]. Juh et al. compared PSP
patients with PD, MSA and controls, and found significant
metabolic impairments in the caudate nucleus, thalamus,
midbrain, and cingulate gyrus [156]. Thalamic hypometa-
bolism was also a common finding but may not be present
in all cases [154, 156]. To distinguish PSP from MSA and
CBS, Botha et al. recently proposed the ‘pimple sign’ – an
oval/round-shaped region representing midbrain hypome-
tabolism on FDG-PET images. This sign had a highspecificity (100%) but low sensitivity (29%) in the ‘definite’
PSP group (PSP-R) [160].
18F-FDG-PET reveals an asymmetric hypometabolism
in the basal ganglia, thalamus and frontoparietal cortical
regions among CBS patients, contralateral to the clinic-
ally affected side [153, 161]. Niethammer et al. recently
utilized spatial covariance analysis to identify a metabolic
pattern in clinically-diagnosed CBS patients versus
controls [161]. The pattern was characterized by bilat-
eral, asymmetric metabolic reductions including fronto-
parietal cortex, thalamus, and caudate nucleus, which
distinguished CBS from MSA, although not from PSP
[161]. Distinction between CBS and PSP was achieved
by using asymmetry scores combined with the PSP-
related metabolic pattern. Parietal lobe hypometabolism
may also help differentiate CBS from PSP and normal
controls [159]. Computer-assisted analysis of FDG-PET
images (obtained at the initial referral) using Statistical
Parametric Mapping (SPM) achieved greater-than 90%
concordance with the clinical diagnosis in PS [162], and
in some cases proved to be superior to the visual inter-
pretation [157]. Such computer-assisted methods show
promise for applications in places where experienced
FDG-PET readers are unavailable.
In DLB, hypometabolism in the occipital cortices along
with less prominent metabolic decline in the hippocam-
pus was observed relative to AD [163]. Lateral occipital
cortex hypometabolism showed the highest sensitivity
(88%), whereas the relative preservation of posterior cin-
gulate metabolism (the ‘cingulate island sign’) achieved
the highest sensitivity (100%) for diagnosing DLB [164].
Patients with PDD and DLB may exhibit a similar pat-
tern of glucose hypometabolism involving bilateral infer-
ior, medial frontal and right parietal regions, although
when compared directly, a more prominent hypometa-
bolism involving the anterior cingulate cortex became
evident among the DLB cases [165].
Analysis of resting-state FDG-PET data using spatial
covariance method has identified reproducible metabolic
patterns in PD and atypical PS. Eidelberg and colleagues
identified a PD-related pattern (PDRP) characterized by
increased pallido-thalamic and pontine metabolic activ-
ity, with relative declines in SMA, premotor cortex, and
parietal association regions [166]. PDRP expression
showed a linear relationship with motor assessments,
and distinguished PD from atypical PS and controls
[167]. Similarly, a distinct PD-related cognitive pattern
(PDCP) was identified involving metabolic reductions
mainly in the medial frontal and parietal association
regions, with relative increases in cerebellar cortex and
dentate nuclei [166]. PDCP expression correlated with
memory and executive performances in PD, and ap-
peared unaltered by routine antiparkinsonian treatment
[168]. Specific patterns of abnormal metabolic activity
Clinical viewpoint
In patients with parkinsonism presenting with atypical features (see list
immediately below), we recommend as a minimum that structural
imaging with high resolution brain MRI be pursued, including
volumetric T1, T2/FLAIR, gradient-recalled echo and/or SWI sequences.
This will allow for visualization of regional atrophy patterns and
neuroimaging signatures seen in some atypical parkinsonian disorders,
and exclude structural lesions such as tumours and vascular pathology
(e.g., strokes, white matter hyperintensities, microbleeds). In complex
cases, perfusion SPECT or FDG-PET, as well as DAT-SPECT may be
considered to help sort out the differential diagnosis.
Atypical features
- Poor response to at least 900 mg total daily dose of levodopa
- Rapidly progressive course of parkinsonism
- Early falls
- Early dysphagia
- Other neurological signs (e.g., upper motoneuron findings,
cerebellar features, supranuclear gaze palsy)
- Early dysautonomia
- Early prominent cognitive impairment or dementia
- Early prominent behavioural changes
- Early prominent language changes
- Apraxia
- Early psychotic features
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patients [169]. Relative to controls, the MSA-related pat-
tern was identified by metabolic declines in the putamen
and cerebellum; whereas, the PSP-related pattern was
characterized by decreased metabolism in the brainstem
and medial frontal cortex [166, 169].
Amyloid imaging
Amyloid PET commonly shows greater cortical Aβ
deposition in AD patients relative to DLB, PDD, PD and
normal controls. In 80% of DLB patients, an elevated
11C-PIB uptake was observed in cortical association
areas, cingulum and striatal regions versus controls,
while normal uptake was detected in 80% of PDD and
all PD subjects [170]. Similarly, a greater mean precu-
neus 11C-PIB uptake was detected in DLB patients
versus PD, PD-MCI and PDD that correlated with cogni-
tive decline [171]. Although, most studies find greater
11C-PIB cortical retention in DLB versus PD/PDD pa-
tients, some studies have not found noteworthy differ-
ences [172], which may be due to variability in the
underlying pathology. When PD and PDD patients were
contrasted, most studies revealed no differences in 11C-
PIB binding; however, when subjects were reclassified as
Aβ-positive and Aβ-negative based on a study-defined
threshold, the PDD group contained a greater propor-
tion of Aβ-positive subjects indicating the potential
contribution of amyloid pathology to cognitive decline
in PDD [173]. Possession of at least one Apolipoprotein
E (APOE) ɛ4 allele was associated with greater 11C-PIB
retention in DLB, PDD and PD-MCI [171].
The presence of Aβ pathology in DLB may influence the
timing of dementia onset relative to motor symptoms, the
severity of cognitive impairment, as well as dementia pro-
gression [171, 172]. Neuropathological studies confirm
these findings by demonstrating greater amyloid pathology
in DLB versus PDD/PD [174] and in PDD versus PD
[175]. Claassen et al. observed glucose hypometabolism in
regions corresponding to Aβ deposition in DLB, whereas
amyloid abnormalities were virtually absent in MSA [176].
Another amyloid radiotracer with a high affinity for Aβ,
18F-florbetaben, produced results comparable to 11C-PIB
and re-confirmed greater neocortical Aβ loads in AD
patients relative to PD, DLB and normal controls [177].
Tau imaging
Spurred by the success of 11C-PIB imaging in quantifying
Aβ loads, recent efforts have been directed towards devel-
oping novel probes to reliably estimate tau accumulation
in human brains. Notable challenges of this technique
include: 1) the intracellular nature of most tau aggregates,
2) multiple conformations of tau isoforms in the brain,
and 3) higher Aβ brain concentrations relative to tau.
Other tracer-specific challenges include: 1) the ideal tracerlipophilicity to achieve adequate tracer permeability and
clearance, 2) the need for greater selectivity relative to Aβ
especially in AD brains, and 3) faster kinetics to reduce
toxicity and facilitate timely clearance [161]. Several
novel fluorine-18 labelled ligands have been developed
that include: 2-(1-(6-[(2-[18F]fluoroethyl)(methyl)amino]-2-naphthyl)ethylidene)malononitrile (18F-FDDNP); quin-




ropyridin-3-yl)-5H-pyrido [4,3-b]indole (18F-T807, known
as 18F-AV-1451); as well as 11C-labelled phenyl/pyridi-
nyl-butadienyl-benzothiazoles/benzothiazolium deriva-
tive (11C-PBB3) [178]. Quantifying and determining
the topological distribution of tau is crucial to further
understand the progression of tauopathies in vivo, to
clarify the role of neurofibrillary tangles in AD along
with their Aβ plaques associations, as well as to im-
prove the sensitivity and specificity of diagnosing PSP
and CBD.
Kepe et al. applied 18F-FDDNP PET in 15 patients with
PSP and detected tracer retention in regions known to be
involved in PSP pathology [179]. Subcortical uptake was
observed in striatum, thalamus, subthalamus, midbrain
and cerebellar white matter regions (versus PD), and high
midbrain and subthalamic uptake distinguished PSP
patients from PD and controls [179]. 11C-PBB3 tracer was
shown by Maruyama et al. to bind to tau inclusions in
PSP and CBD postmortem brain tissues [180].
Recently, 18F-AV-1451 was reported by Marquié et al.
to bind tau lesions composed primarily of paired helical
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straight tau filaments in 4-repeat tauopathies, or to
lesions containing β-amyloid, α-synuclein, or TDP-43
aggregates [181, 182]. An off-target binding to
NM-containing neurons in the midbrain was also identi-
fied [182, 183]. This was pursued by Hansen et al., demon-
strating a visually apparent decline in 18F-AV-1451 signal
in the midbrain of PD patients versus controls [183].
Although, nigral 18F-AV-1451 signal showed no correl-
ation with the disease duration, motor dysfunction, or stri-
atal 123I-FP-CIT values, its utility as an in vivo marker of
NM-containing cells in the SN was supported. Lower 18F-
AV-1451 binding in SN in PD was confirmed by another
study, including lack of correlation with motor severity in
both PD and PSP [184]. Relatively greater (but non-
significant) 18F-AV-1451 signal was detected in putamen,
globus pallidus, subthalamic and dentate nucleus in PSP
versus controls, along with variable non-specific subcor-
tical binding in controls [184]. Similarly, no statistically
significant differences in 18F-AV-1451 uptakes were found
in cortical or subcortical regions in PSP versus PD or con-
trols bringing into question the reliability of this tracer in
primary tauopathies, such as PSP (Personal communica-
tion, Strafella AP). Smith et al. found elevated 18F-AV-
1451 retention in the basal ganglia of PSP patients, albeit
with extensive overlap and age-dependent increases in
both groups [185]. Compared to AD, Whitwell et al. re-
ported a greater 18F-AV-1451 signal in cerebellar dentate
and pallidum of PSP patients, whereas, signal across the
cortex was elevated in AD versus PSP [186]. Future efforts
need to be directed towards developing improved tracers
as well as to test the usefulness of existing tracers in clin-
ical studies.Imaging neuroinflammation
In the context of neurodegenerative diseases, the term
'neuroinflammation' refers to chronic immune response
in the central nervous system (CNS), characterized by
local cellular and microvasculature changes associated
with microglial recruitment and proinflammatory cyto-
kine production. Microglia are the resident macrophages
and part of the innate immune response of the CNS,
representing approximately 10% of the brain’s cell popula-
tion. In addition to being important players in neurodeve-
lopment and maturation, microglia are involved in tissue
repair, maintenance, and regeneration. Emerging evidence
highlights that, depending upon the injury and microenvi-
ronmental conditions, microglia-mediated inflammatory
processes may aggravate injury and contribute to the
cascade of events leading to neurodegeneration [187]. A
common PET ligand for imaging neuroinflammation has
been 1-(2-chlorophenyl-N-methylpropyl)-3-isoquinoline-
carboxamide (PK11195), which binds to 18 kDamitochondrial translocator protein (TSPO, formally per-
ipheral benzodiazepine receptor). Upregulation of TSPO
is indicative of augmented microglial activation in the
CNS.
Using 11C-(R)-PK11195, Gerhard et al. reported in-
creased binding in the pons, basal ganglia, and frontal
and cingulate cortices in PD versus controls. However,
no correlation of microglial activity with clinical severity
or 18F-dopa was observed [188]. The extent of microglial
activation remained stable in a subsample followed lon-
gitudinally for two years [188]. Conversely, Ouchi et al.
found elevated binding in the midbrain contralateral to
the clinically affected side in PD (versus controls),
correlating with putaminal DAT levels (using 11C-β-
CFT-PET) and motor severity [189]. In PDD, widespread
microglial activation compared to controls was found in
the anterior/posterior cingulate, striatum as well as in
the frontal, temporal, parietal and occipital cortices, with
maximal parieto-occipital involvement. The spatial
extent of cortical binding was greater in PDD than in
PD [190]. Elevated tracer binding in MSA (versus con-
trols) was observed in the prefrontal cortex, putamen,
pallidum, pons, and SN, consistent with the known
neuropathological distribution [191]. Similarly, increased
microglial activity in PSP was demonstrated in the basal
ganglia, midbrain, frontal lobe, and cerebellum relative
to controls [188]; while in CBS, elevated microglial re-
sponse was noted in the caudate nucleus, putamen, SN,
pons, pre/postcentral gyrus and frontal lobe [192].
Recently, Fan et al. evaluated correlations among micro-
glial activation (using 11C-(R)-PK11195), glucose metabol-
ism (18F-FDG), and amyloid load (11C-PIB) in AD, MCI,
and PDD patients. An inverse correlation was noted
between microglial activation and glucose metabolism in
temporo-parietal cortex in AD and PDD; whereas, a posi-
tive correlation was apparent between microglial activa-
tion and amyloid load in AD and MCI [193].
A new tracer, 11C-DPA713, has been reported to have
a greater sensitivity for TSPO and may emerge as a
better indicator of global microglial activation than 11C-
(R)-PK11195 [194]. Limitations of imaging studies of
neuroinflammation are small sample sizes and lack of
autopsy-verified diagnosis. A viable application of this
technique is in monitoring therapeutic responses in clin-
ical trials.
[123I]metaiodobenzylguanidine myocardial
scintigraphy in Parkinsonian disorders
[123I]Metaiodobenzylguanidine (123I-MIBG) is a radioio-
dinated analogue of guanethidine that is taken up by the
postganglionic adrenergic neurons using cellular mecha-
nisms identical to norepinephrine. Upon depolarization,
123I-MIBG is released into the synaptic cleft, like norepin-
ephrine, but remains unmetabolized. This uptake and
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postganglionic sympathetic fiber integrity and function
[195]. 123I-MIBG myocardial scintigraphy has traditionally
been utilized to assess sympathetic nerve damage in
cardiovascular diseases. More recently, its application in
the differential diagnosis of neurodegenerative diseases
has emerged, especially in α-synucleinopathies where pro-
found cardiovascular dysautonomia can be observed
[196]. Uptake of 123I-MIBG in myocardial scintigraphy is
often reported as a heart-to-mediastinum (H/M) ratio of
count densities, whereas washout rate index may also be
assessed using early and delayed images.
Impairments in 123I-MIBG H/M ratios were found to
be independent of the duration and severity of auto-
nomic and parkinsonian symptoms [197, 198], intensity
of anti-parkinsonian therapy [199], and striatal denerv-
ation as assessed using (+)-11C-dihydrotetrabenazine
(11C-DTBZ) PET in PD [200]. Marked decrease in 123I-
MIBG uptakes were detected relative to controls, even
at the early PD stages in the absence of clinically appar-
ent dysautonomia, indicating this technique as a useful
diagnostic tool for PD [201–203]. Patients with PSP,
MSA and CBS exhibit normal or mildly reduced
uptakes, which may help differentiate PD from atypical
PS [200, 204]. Many studies report markedly reduced
123I-MIBG H/M ratios in patients with LBD [200, 204,
205], compared to normal ratios in AD and healthy con-
trols [197, 205]. 123I-MIBG scintigraphy can distinguish
LBD from other dementias with high discriminative
accuracy (sensitivity 95% and specificity 87%) [205]. This
technique was found to be more sensitive than occipital
hypoperfusion using SPECT [206] and superior to CSF
Aβ and tau biomarkers, in differentiating DLB from AD
[207]. King et al. conducted a pooled analysis of 123I-
MIBG studies and identified two distinct clusters that
were well separated at an optimal H/M ratio of 1.77
[208]. This meta-analysis allowed discrimination be-
tween PD and MSA, as well as between the two most
common neurodegenerative dementias of AD and DLB
at a critical 123I-MIBG uptake threshold [208]. Similarly,
a meta-analysis of 19 studies using myocardial scintig-
raphy presented a pooled sensitivity of 88% in detecting
PD, and a pooled specificity of 85% in distinguishing PD
from other PS [209]. A recent study by Sudmeyer et al.
utilized a multimodal approach using 123I-FP-CIT, 123I-
IBZM and 123I-MIBG and proposed an algorithm that
distinguished atypical PS from PD with 94% sensitivity
and specificity [210]. Similarly, Sengoku et al. assessed
olfactory bulb and tract volume together with H/M ratio
of 1.6 to optimally distinguish PD patients from an atyp-
ical PS group, comprised of MSA, PSP and CBS partici-
pants [211].
Myocardial scintigraphy using 123I-MIBG is a useful
technique that can offer valuable adjunctive evidence inclinically uncertain cases. However, there is a need to val-
idate this technique in larger pathologically-confirmed co-
horts to account for the confounding effects of mixed and
vascular pathologies. Various cardiovascular morbidities,
latent cardiac disorder and medications may damage the
postganglionic sympathetic neurons leading to false-
positive findings. Additionally, 123I-MIBG H/M ratios may
also decrease with age and show gender-specific variations
[212], making it essential to use well-matched subgroups
in clinical investigations (Table 3).
Transcranial sonography
Transcranial sonography (TCS) is a low-cost, non-
invasive and widely available B-mode neuroimaging
technique that uses ultrasound to assess the echogenicity
of brain tissues through the intact cranium. TCS is com-
monly applied using a 2.5 MHz phased-array transducer
placed at the preauricular site across the transtemporal
bone window. SN is identified at the mesencephalic plane
within the brainstem, which appears as a butterfly-shaped
structure of low echogenicity surrounded by hyperecho-
genic basal cisterns. Visualization of the basal ganglia can
be achieved in the plane of the third ventricle. A limitation
with TCS is that it may not be feasible in some subjects
due to an insufficient bone-window.
Substantia nigra echogenicity
Increased echogenicity of the SN, often visible as an
enlarged ‘patchy’ region near the lateral midbrain, is a
characteristic TCS finding in PD [213, 214]. This ‘echo-
feature’ shows no consistent correlation with the disease
duration or severity [213, 215], although one such study
did observe this finding [216]. In a five-year follow-up
study, Berg at al. established that the area of SN hypere-
chogenicity remains stable over time in PD patients
[217], implicating its role as an early (or possibly preclin-
ical) ‘trait’ marker or feature of PD that is independent
of disease duration or severity. Spiegel at al. employed
123I-FP-CIT SPECT together with TCS and found no
association between presynaptic DAT degeneration and
SN hyperechogenicity [218], suggesting independent
pathophysiological mechanisms for these two modalities.
Notably, healthy subjects with enlarged SN echogenic
areas but without any motor deficits exhibited marked
decrease in striatal 15F-dopa on PET, providing evidence
of dysfunction in the SN; however, due to the cross-
sectional nature of this study, it is unknown if these
subjects went on to develop parkinsonism [219, 220].
Another study showed 57% of PD patients with bilateral
and 43% with unilateral SN hyperechogenicity, propos-
ing that the bilateral finding may be a more specific
marker of PD [215].
Studies report hyperechogenicity of SN (especially
when marked) to be highly sensitive (90-91%) and
Table 3 Common SPECT, PET, myocardial scintigraphy, and transcranial sonography findings, compared to healthy controls
Imaging Modality Measure Neurodegenerative Disorders Relevant References
Synucleinopathies Tauopathies
Lewy Body Spectrum Disorders
HC PD-n PD-t PD-MCI PDD DLB MSA PSP CBS AD
SPECT
ST presynaptic DAT density ○ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ○ 104-111
ST postsynaptic D2 receptor density ○ ↑ ○ × ○ ↓ ○ ↓ ↓ ↓ ○ ↓ ○ 105, 108, 111, 129-131
PET
ST presynaptic DAT or AADC activity ○ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ○ 139-145
ST postsynaptic D2 receptor density ○ ○ ↑ ○ × × ↓ ↓ ↓ ↓ ○ 143, 148-151
Cerebral amyloid 11C-PIB uptake ○ ○ ○ ○ ↑ ○ ↑ ↑ ○ ○ ○ ↑ ↑ 170-173
Cerebral tau Tau tracers uptake ○ ○ ○ ○ ○ ↑ ○ ↑ ○ ○ or ↑ ○ ↑ ↑ 179-186
Neuroinflammation Microglial activity ○ ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ 188-193
Scintigraphy
Myocardial 123I-MIBG uptake ○ ↓ ↓ ↓ ↓ ↓ ○ ↓ ○ ↓ ○ ↓ ○ 201-205
TC Sonography
Substantia nigra Echogenicity ○ ↑ ↑ ↑ × ↑ ↑ ○ ↑ ↑↓ ↑↓ ○ ↑ 213, 214, 223-227
Lentiform nucleus Echogenicity ○ ↑ ↑↓ ↑↓ × ↑ ↑ ↑ ↑↓ ○ ↑ ○ ↑ 215, 223, 225, 226
Legend: ○ = normal; ↓ = decrease; ↑ = increase, ↑↓ = increase or decrease or normal; ○ ↑ = predominantly normal with increases also reported; ○ ↓ = predominantly
normal with decreases also reported; × = not specifically reported in literature
Abbreviations: AADC, aromatic amino acid decarboxylase; AD, Alzheimer’s disease; CBS, corticobasal syndrome; D2, dopamine D2; DAT, dopamine transporters; DLB,
dementia with Lewy bodies; HC, healthy controls; MSA, Multiple system atrophy; PDD, Parkinson’s disease dementia; PD-MCI, Parkinson’s disease with mild
cognitive impairment; PD-n, drug-naïve Parkinson’s disease; PD-t, drug-treated Parkinson’s disease; PSP, progressive supranuclear palsy; ST, Striatal; TC, transcranial;
11C-PIB, 11C-labelled Pittsburg Compound B; 123I-MIBG, 123I-labelled metaiodobenzylguanidine
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PSP subjects [214, 221]. It is important to note that SN
hyperechogenicity is not a single specific marker of PD
as it may also be observed in about 9% of healthy indi-
viduals and 16% of essential tremor patients [219, 222].
This ‘echofeature’ is also observed in DLB, PDD and
CBS patients to varying degrees [223, 224]. Walter et al.
found all DLB, 97% PDD and 94% PD patients with at
least unilateral SN hyperechogenicity; whereas 80% of
DLB presented with marked bilateral findings [223].
Other studies report 66-88% of CBS patients with mark-
edly echogenic SN [224, 225], whereas, 0-20% of the PSP
patients presented with this feature [224–226]. A recent
investigation further compared PSP-R and PSP-P pheno-
types, and found SN hyperechogenicity in 6/7 PSP-P pa-
tients as compared to 1/27 PSP-R, implicating that this
characteristic may be specific to PSP-P [227]. Walter
et al. tried to discriminate DLB from PDD using TCS by
combining SN echogenic sizes, asymmetry indices and
age of onset, and observed high diagnostic accuracy
(sensitivity 96%, specificity 80%) [223]. The etiology of
SN hyperechogenicity remains unclear and may reflect
higher levels of iron in SN [220]. It is plausible that
other factors in addition to iron accumulation may con-
tribute to this characteristic, as other iron-rich regions
of the brain, such as the pallidum, appear normal in
TCS.Lentiform nucleus echogenicity
Hyperechogenicity of the LN is a feature frequently
observed in some atypical PS. Normal SN echogenicity
together with hyperechogenic LN strongly supports a
diagnosis of atypical PS (positive predictive value, 0.96)
[215]. Specifically, this echogenic pattern indicated
MSA-P or PSP diagnosis with 100% sensitivity, but with
a relatively low specificity of 59% [226]. Normal SN
echogenicity alone supported a diagnosis of MSA-P ra-
ther than PD (sensitivity 90%; specificity 98%), whereas
LN hyperechogenicity alone may not be helpful in the
differential diagnosis of PS as 25-30% of PD and PSP
patients also display this feature [226]. Sadowski at al.
compared TCS patterns in PSP and CBS patients, and
detected normal LN echogenicity in all 11 CBS patients
[225]. The authors noted that LN hyperechogenicity
with coexisting SN normoechogenicity can help exclude
CBS as a potential diagnosis among patients with atyp-
ical PS [225]. Walter et al. reported that a combination
of hyperechogenic LN with third-ventricle dilation of
greater than 10-mm suggests a diagnosis of PSP over
PD, with 84% sensitivity and 98% specificity [226].
Conclusions
Extensive neuropathological overlap and clinical hetero-
geneity in disease presentation and progression, in part,
challenges the differential diagnosis of PD and atypical
Saeed et al. Translational Neurodegeneration  (2017) 6:8 Page 20 of 25PS, especially at early stages. Imaging biomarkers can
provide supportive evidence to aid in the diagnostic
process. Multiple biomarkers derived from different
imaging modalities can provide distinct information
about neuroanatomical and pathophysiological processes
associated with the underlying disease. This ‘multimodal
approach’ can assist in making early, objective, and
confident diagnostic decisions in clinical as well as re-
search settings. Further research is needed to improve
measurement techniques, standardize research proto-
cols, and identify effective and pathology-specific radio-
tracers. Efforts are also needed to replicate these
findings in larger well-characterized cohorts. Future clin-
ical decision-making and personalized treatment regi-
mens are sure to rely upon multimodal in vivo imaging,
not only to improve the diagnostic accuracy but also to
track treatment effectiveness in clinical trials.
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